Literature DB >> 15599164

Substantiating the concerns about recombinant human activated protein C use in sepsis.

Katherine J Deans, Peter C Minneci, Steven M Banks, Charles Natanson, Peter Q Eichacker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15599164     DOI： 10.1097/01.ccm.0000148090.94378.6a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  5 in total

1.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

2.  Increasing evidence that the risks of rhAPC may outweigh its benefits.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

3.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

Review 4.  Recombinant human activated protein C for severe sepsis in neonates.

Authors:  Ranjit I Kylat; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

5.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.